- Home
- MAGN vs DBVT Comparison
MAGN vs DBVT Comparison
Compare MAGN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGN
- DBVT
- Stock Information
- Founded
- MAGN 1864
- DBVT 2002
- Country
- MAGN United States
- DBVT France
- Employees
- MAGN N/A
- DBVT N/A
- Industry
- MAGN Paper
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAGN Basic Materials
- DBVT Health Care
- Exchange
- MAGN Nasdaq
- DBVT Nasdaq
- Market Cap
- MAGN 67.4M
- DBVT 67.8M
- IPO Year
- MAGN N/A
- DBVT N/A
- Fundamental
- Price
- MAGN $18.70
- DBVT $3.04
- Analyst Decision
- MAGN
- DBVT Strong Buy
- Analyst Count
- MAGN 0
- DBVT 2
- Target Price
- MAGN N/A
- DBVT $22.50
- AVG Volume (30 Days)
- MAGN 587.8K
- DBVT 371.9K
- Earning Date
- MAGN 02-15-2025
- DBVT 11-06-2024
- Dividend Yield
- MAGN N/A
- DBVT N/A
- EPS Growth
- MAGN N/A
- DBVT N/A
- EPS
- MAGN N/A
- DBVT N/A
- Revenue
- MAGN $2,175,000,000.00
- DBVT $12,515,000.00
- Revenue This Year
- MAGN N/A
- DBVT N/A
- Revenue Next Year
- MAGN N/A
- DBVT $2,860.00
- P/E Ratio
- MAGN $31.47
- DBVT N/A
- Revenue Growth
- MAGN N/A
- DBVT 125.54
- 52 Week Low
- MAGN $15.86
- DBVT $0.44
- 52 Week High
- MAGN $35.23
- DBVT $4.50
- Technical
- Relative Strength Index (RSI)
- MAGN N/A
- DBVT 56.98
- Support Level
- MAGN N/A
- DBVT $2.74
- Resistance Level
- MAGN N/A
- DBVT $3.42
- Average True Range (ATR)
- MAGN 0.00
- DBVT 0.26
- MACD
- MAGN 0.00
- DBVT -0.12
- Stochastic Oscillator
- MAGN 0.00
- DBVT 25.21
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.